Literature DB >> 17924409

Cytologic examination of bronchoalveolar lavage fluid from immunosuppressed patients.

Ali Mohammed Al-Za'abi1, Scott MacDonald, William Geddie, Scott L Boerner.   

Abstract

Pulmonary infiltrates in immunocompromised patients frequently represent infections. This study was undertaken to evaluate cytologic examination of bronchoalveolar lavage samples and the value of different preparations and silver staining. Over 6 mo, 336 samples were collected from 155 immunosuppressed patients in whom both cytologic and microbiologic studies were performed. In 27 samples, the cytology, microbiology or both demonstrated the presence of infectious agents. In four cases, cytology identified neoplastic process. Cytology had a sensitivity of 34.6% for detection of infection, which increased to 42.9% when Cytomegalovirus was excluded. Cytology detected 6 of 15 cases of Aspergillus, including three cases not detected by microbiology and 3 of 4 cases of Pneumocystis, but did not identify any of the Cytomegalovirus cases. The type of preparations did not affect detection of the organism when present in cytologic samples and silver staining did not appear to have added value in examination of these samples. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17924409     DOI: 10.1002/dc.20741

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  2 in total

1.  Inflammation on bronchoalveolar lavage cytology is associated with decreased chronic lung allograft dysfunction-free survival.

Authors:  Nancy Y Greenland; Fred Deiter; Daniel R Calabrese; Steven R Hays; Jasleen Kukreja; Lorriana E Leard; Nicholas A Kolaitis; Jeffrey A Golden; Jonathan P Singer; John R Greenland
Journal:  Clin Transplant       Date:  2022-03-12       Impact factor: 3.456

Review 2.  Diagnosis and management of lung infections.

Authors:  Dawn E Jaroszewski; Brandon J Webb; Kevin O Leslie
Journal:  Thorac Surg Clin       Date:  2012-08       Impact factor: 1.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.